Form 4: IQVIA CEO Bousbib Granted 78,264 Stock Appreciation Rights

IQVIA Holdings Inc. CEO Ari Bousbib was granted 78,264 stock appreciation rights, vesting annually starting February 2027.

Summary

• Ari Bousbib, who serves as Chairman, Chief Executive Officer, and President of IQVIA Holdings Inc., was granted 78,264 Stock Appreciation Rights (SARs).
• The Stock Appreciation Rights have an exercise price of $192.67.
• These SARs are scheduled to vest in three annual installments, with the first installment beginning on February 9, 2027.
• The expiration date for these Stock Appreciation Rights is February 9, 2036.
• Following this reported transaction, Mr. Bousbib beneficially owns 78,264 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of executive incentives with long-term shareholder value, a standard practice for retaining key leadership.

Positives

• The grant of 78,264 Stock Appreciation Rights to the CEO aligns management incentives directly with long-term shareholder value creation.
• The multi-year vesting schedule (three annual installments starting February 2027) and a long expiration date (February 2036) suggest a sustained commitment from the CEO to the company's future performance.

Risks

• The value of the Stock Appreciation Rights is contingent upon the future appreciation of IQVIA Holdings Inc.'s stock price above the exercise price of $192.67, meaning there is no guaranteed payout if the stock does not perform as expected.

Future Outlook

The grant of long-term equity incentives to the CEO indicates a strategic focus on future growth and shareholder value creation, aligning executive compensation with the company's long-term performance objectives.

Management Comments

• Ari Bousbib holds the titles of Chairman, Chief Executive Officer & President of IQVIA Holdings Inc.

Industry Context

StockSavvy.ai notes that granting Stock Appreciation Rights (SARs) is a common executive compensation practice within the healthcare and life sciences technology industry. This strategy aims to incentivize long-term performance and align management interests with shareholder returns, consistent with typical executive incentive structures observed across large-cap companies in the sector.

Comparison to Industry Standards

• The grant of SARs with a multi-year vesting schedule is a standard practice for executive compensation, comparable to grants at companies like Thermo Fisher Scientific or Danaher Corporation, which also utilize performance-based equity to retain and incentivize top leadership.
• The exercise price of $192.67, which is the market price at the time of grant, is typical for SARs and stock options, ensuring that the executive benefits only from future stock price appreciation.
• The total number of SARs granted (78,264) represents a significant equity stake, which would typically be evaluated against Mr. Bousbib's overall compensation package and IQVIA's market capitalization to fully assess its relative size compared to peers.

Stakeholder Impact

• Shareholders: The grant of SARs aligns the CEO's financial interests with long-term shareholder value creation, as the SARs only gain value if the stock price appreciates.
• Employees: May view this as a signal of management's confidence in the company's future, potentially boosting morale and indicating stability in leadership.

Next Steps

• The Stock Appreciation Rights will begin to vest in three annual installments starting February 9, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of executive compensation in the form of Stock Appreciation Rights to the CEO. While it aligns management incentives with shareholder interests, it does not present new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure for a publicly traded company.

Keywords

IQVIA Holdings Inc., IQV, Ari Bousbib, Stock Appreciation Rights, SARs, Insider Transaction, Executive Compensation, Form 4, Equity Grant